The middle of 2026 marks a significant turning point for patients with refractory Rheumatoid Arthritis as vesicle-mediated cytokine suppression enters standard clinical practice. New data from the 2026 EULAR congress suggests that targeted biological particles can silence the localized "cytokine storms" in joints without compromising the patient's global immune system. This innovation is being...
Tiếng Việt 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)